Trials / Completed
CompletedNCT05200871
Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)
Humanistic Burden of Rare Kidney Diseases: Understanding the Impact of FSGS and IgAN on Patients and Caregivers Study (HONUS) - A Multi-National, Cross-Sectional Survey Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 487 (actual)
- Sponsor
- Travere Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this observational study is to assess humanistic burden among adults and children/adolescents with FSGS and IgAN as well as the burden and impact for patient care-partners in six countries (United States \[US\], United Kingdom \[UK\], France, Germany, Italy and Spain).
Conditions
Timeline
- Start date
- 2022-02-05
- Primary completion
- 2023-10-31
- Completion
- 2023-10-31
- First posted
- 2022-01-21
- Last updated
- 2024-02-21
Locations
6 sites across 3 countries: United States, Germany, Spain
Source: ClinicalTrials.gov record NCT05200871. Inclusion in this directory is not an endorsement.